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In this issue of Cancer Cell, Wang and colleagues report that CARM1, a protein arginine methyltransferase,
specifically methylates BAF155/SMARCC1, a core subunit of the SWI/SNF chromatin remodeling/tumor
suppressor complex. This modification facilitates the targeting of BAF155 to genes of the c-Myc pathway
and enhances breast cancer progression and metastasis.While long studied for its role in modu-
lation of chromatin structure and tran-
scriptional regulation, in the last several
years, the SWI/SNF (BAF) chromatin
remodeling complex has emerged as
one of the most widely mutated group of
genes in human cancer. The complex
utilizes the energy from ATP hydrolysis
to mobilize nucleosomes and modulate
chromatin structure. Initial discovery of
the complex came from yeast in which
mutations in genes encoding the SWI/
SNF subunits were found essential for
transcriptional activation of mating type
SWItching and sucrose metabolism, the
latter resulting in a sucrose nonfermenting
(SNF) phenotype. In mammals, the
complex consists of approximately 15
subunits that include both ubiquitously
expressed core subunits, such as
BAF155/SMARCC1, as well as a number
of lineage-specific subunits often en-
coded by gene families (Wu et al., 2009).
The complex has been implicated in
the dynamic transcriptional regulation of
genes involved in fate specification,
proliferation, and differentiation and also
in various types of DNA repair.
The SWI/SNF complex was initially
linked to cancer in 1998, when biallelic
inactivating mutations in the SMARCB1/
SNF5/INI1/BAF47 subunit were identified
in aggressive pediatric rhabdoid cancers
(Versteege et al., 1998). Mouse models
established SMARCB1 as a bona fide
and potent tumor suppressor (Wilson
and Roberts, 2011). With the advent
of cancer genome sequencing efforts,
it became clear that SMARCB1 was not
the only subunit mutated in cancer,
because recurrent mutations in at leasteight SWI/SNF subunits were also iden-
tified, collectively occurring in 20% of
human cancers (Kadoch et al., 2013).
This has resulted in interest in identifying
mechanisms by which activity of the
SWI/SNF complex is regulated, with the
hope that such mechanistic understand-
ing may reveal novel opportunities for
therapeutic intervention.
Arginine methylation, catalyzed by a
family of protein arginine methyltrans-
ferases, has long been implicated in the
regulation of gene transcription and
translation. Coactivator-associated argi-
nine methyltransferase-1 (CARM1), one
of nine members of the family, has been
shown to methylate substrates involved
in chromatin remodeling and gene tran-
scription including histone H3 (at R17),
histone acetyltransferases (p300/CBP),
splicing factors (CA150, SAP49, SmB,
and U1C), and RNA-binding proteins
(PABP1, HuR, and HuD) (Bedford and
Clarke, 2009). CARM1 has also been
implicated in cancer. High-level expres-
sion of CARM1 has been observed in
several cancers, including those of pros-
tate, colon, and breast, with levels higher
in metastatic breast cancer than in pri-
mary breast cancer. CARM1 has also
been shown to stimulate breast cancer
growth and serves coactivator roles for
numerous proteins that have been impli-
cated in cancer, including p53, E2F1,
NF-kB, b-catenin, and steroid hormone
receptors (Bedford and Clarke, 2009).
However, the mechanisms by which
CARM1 may contribute to breast cancer
growth, and whether this activity depends
upon enzymatic methylation of targets,
remains poorly understood.Cancer CellIn this issue of Cancer Cell, Wang and
colleagues investigate these mechanisms
by searching for novel CARM1 substrates
in breast cancer cells (Wang et al., 2014).
The authors inactivated CARM1 in a
breast cancer cell line in order to identify
differentially methylated proteins via a
methylation-specific antibody. Interest-
ingly, a 90% knockdown of CARM1 with
small hairpin RNAs had only a modest
effect on CARM1 level and activity,
necessitating the authors to create a full
knockout with the genome-editing zinc
finger nuclease technology. The proteins
methylated only in cells with intact
CARM1 included the SWI/SNF subunit
BAF155. Through a series of well-de-
signed biochemical assays, the authors
confirmed that BAF155 is a bona fide
CARM1 substrate and identified arginine
1064 (R1064) as the sole methylation site.
Given the emerging links between the
SWI/SNF chromatin remodeling complex
and cancer, Wang et al. (2014) sought to
investigate the mechanistic consequence
of this modification and to evaluate its
cancer relevance. They first tested the
effect of BAF155 methylation upon its
association with chromatin by generating
a methylation-defective BAF155R1064K
mutant and used ChIP-seq to compare
its binding to that of wild-type BAF155
(BAF155WT). BAF155R1064K was readily
incorporated into the SWI/SNF complex
and showed overlap with the binding of
BAF155WT, the majority of which (74%)
was methylated. However, there were
also substantial differences, suggesting
that CARM1-mediated methylation of
BAF155 affected its targeting. Subse-
quent analysis of the genes preferentially25, January 13, 2014 ª2014 Elsevier Inc. 3
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Figure 1. Methylation of BAF155 by CARM1 Alters SWI/SNF
Targeting to Activate c-Myc, Migration and Proliferation Pathways
CARM1 methylates BAF155, a core subunit of the SWI/SNF complex,
at R1064, which facilitates binding and activation of c-Myc, migration, and
proliferation pathways.Methylated BAF155may exist in a subcomplex lacking
BRG1 and BAF53.
Cancer Cell
Previewsbound by methylation-com-
petent BAF155WT revealed
meiosis and c-Myc pathways
as the two most significantly
enriched pathways. On
several selected targets,
ChIP-PCR confirmed that
methylation of BAF155 cre-
ates novel binding sites and
correlates with increased
expression of the associated
genes. Notably, when bind-
ing of BAF155 was compared
to that of other SWI/SNF
subunits, the authors iden-
tified regions at which
BRG1/SMARCA4, a catalytic
ATPase subunit, and BAF53/
ACTL6A were not detected,
but SNF5/SMARCB1 and
other subunits were. The
authors thus propose that
BAF155 may exist in sub-
complexes capable of bind-
ing chromatin, a novel and
interesting possibility that
awaits confirmation, because
differential antibody affinities
can make such analyseschallenging (Figure 1).
Having identified a role for CARM1-
mediated methylation of BAF155 in
control of the c-Myc pathway, the authors
sought to determine whether this may
contribute to oncogenesis. Immuno-
histochemistry for methylated BAF155
(me-BAF155) on clinical breast cancer
samples revealed that me-BAF155 was
expressed at higher levels in cancer
samples than in normal breast tissues.
Moreover, me-BAF155 also correlated
with advanced stages, with higher levels
of me-BAF155 associated with poor
survival. Importantly, knocking down
BAF155 in MDA-MB-231 cells resulted in
impaired proliferation and migration, an
effect that was rescued by re-expression
of WT BAF155, but not by the methy-
lation-deficient R1064K mutant. This
observation was validated and extended
in vivo in which MDA-MB-231 cells
stably expressing wild-type BAF155,
but not the R1064K mutant, displayed
lung colonization and tumor outgrowth.
Collectively, the results of Wang et al.
(2014) reveal that the elevated levels of
CARM1 and BAF155 in aggressive breast4 Cancer Cell 25, January 13, 2014 ª2014 Elcancer may contribute to pathogenesis
by CARM1-mediated methylation of
BAF155 at R1064, facilitating activation
of pro-oncogenic and metastatic path-
ways. Therapeutic targeting of protein
methyltransferases has recently become
an area of intense interest in drug devel-
opment due to increased recognition of
roles for these enzymes in cancer patho-
genesis. Indeed, two potent and selective
CARM1 inhibitors have been reported
(Copeland et al., 2009), although sub-
stantial work is still needed to determine
whether they can ultimately be made
into drugs. Enthusiasmmay be somewhat
tempered by the finding that knock down
of CARM1 by 90% was insufficient to
mimic the effects of CARM1 knockout,
because this suggests that complete
pharmacologic inhibition might be re-
quired in order to achieve a therapeutic
effect.
The findings of Wang et al. (2014) are
quite interesting given the well-estab-
lished function of several other subunits
of the SWI/SNF complex as tumor sup-
pressors. There is an emerging themesevier Inc.that the cancer-associated
mutations do not inactivate
the SWI/SNF complex, but
rather result in aberrant func-
tion of the residual complex
(Wang et al., 2009; Oike
et al., 2013). Consequently, it
is an exciting possibility that
posttranslational modifica-
tions, such as CARM1-medi-
ated methylation of BAF155,
or altered expression levels
of individual SWI/SNF sub-
units (Liu et al., 2011) may
also alter SWI/SNF function
in a manner that can facilitate,
or block, oncogenesis. It will
also be of interest, and of po-
tential therapeutic relevance,
to elucidate the mechanisms
bywhichmodifications and al-
terations affect the function of
this frequently mutated tumor
suppressor complex.REFERENCES
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